Thursday, January 29, 2015

ATA Highlights New Thyroid Cancer Research

http://www.onclive.com/conference-coverage/ata-2014/ATA-Highlights-New-Thyroid-Cancer-Research

The impact of radioactive iodine (RAI) on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 American Thyroid Association (ATA) Annual Meeting.

The five-day conference, held in Coronado California from October 29 to November 2, 2014, is geared toward endocrinologists, internists, surgeons, nuclear medicine scientists, pathologists, and other healthcare professionals. Presentations at the meeting encompass a wide array of topics in thyroidology, including the treatment of various neoplasms.

One of the more exciting studies presented at the meeting, from researchers at the Massachusetts General Hospital, demonstrated the feasibility of BRAFV600E mutation detection using a blood-based assay in patients with papillary thyroid cancer (PTC). In general, BRAF mutations are associated with a worse overall prognosis, resistance to RAI therapy, and an increased risk of metastases and mortality. Results from the analysis suggest that a blood-based assay could be used for diagnosis, postoperative surveillance, and to monitor treatment response to BRAF inhibitors.

Adding to the importance of BRAF in PTC, researchers from the Beth Israel Deaconess Medical Center found lower levels of large non-coding RNA (LincRNA) neighboring the thyroid peroxidase gene in patients with BRAFV600E-positive PTC. These findings suggest that LincRNA could be involved in the regulation of iodine metabolism associated gene expression, suggesting LincRNA could be used for monitoring patients undergoing treatment.

"The identification of new circulating markers, if validated, should improve both the diagnosis and longitudinal follow-up of patients with papillary thyroid cancer," Robert C. Smallridge, MD, president elect of the ATA, said in a statement.

Differentiated Thyroid Cancer

For patients with differentiated thyroid cancer (DTC), RAI therapy has been utilized as a standard therapy for more than half a decade. An examination of nearly 5000 patients from 1987 to 2012 revealed that thyroidectomy followed by RAI therapy correlated with a survival benefit in patients with high risk DTC. However, this analysis did not find the same benefit in patients with low risk disease, suggesting an optimal setting for RAI use.

Further insight was added through an examination of thyroid hormone suppression therapy (THST) administration over the same timeframe. Overall, moderate but not aggressive THST was associated with improved survival in all DTC stages. Furthermore, the use moderate THSH was predictive of improved disease-free survival following surgery.

"Their findings are important—that these patients don't need to be aggressively suppressed to an undetectable level of TSH, but rather somewhere in what they defined as a moderate hormone level," Naifa L. Busaidy, MD, associate professor at MD Anderson Cancer Center, said in an interview with OncLive. "It’s an interesting study with important findings that a lot of us had a gut feeling about but didn't have the data to back it up. Now we have several thousand patients' data showing that this might be important."

To build on treatment with RAI, researchers looked at the therapy in combination with lithium for patients with metastatic DTC who did not respond to initial RAI therapy. In this study, patients received oral lithium for 7 days, which started 5 days before RAI therapy. With the combination approach, 45% of patients had stable disease at 6 months, resulting in a significant improvement in progression-free survival.

After 10 years of follow up, patients in the combination arm showed slightly higher survival rates than with RAI alone (67.9% vs 66.8%). The median survival with the combination was 126.2 versus 105.4 months, after propensity score matching.

Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) is generally treated with surgery followed by adjuvant therapy. In the past few years, two novel therapies have gained approval as treatments for patients with this rare cancer.

“The biggest challenge we're having now in the field of medullary thyroid cancer, certainly as researchers, is that we don't have a third line, and there are patients now who are getting to that third line. And, unfortunately, now that is a big question mark," Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, said in an interview with OncLive.

To attempt to address this, a study explored a unimolecular micelles conjugated with the somatostatin analog KE108 as a delivery mechanism for the HDAC inhibitor AB3. In a culture, the targeted delivery of the nanocarrier was associated with increased uptake by MTC cells. These early findings suggest the possibility for better therapeutic outcomes with less systemic toxicity.

Thursday, December 4, 2014

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.
In the presentation "Impact of Radioactive Iodine on Survival in Papillary Thyroid Carcinoma," Paritosh Suman, M.D. and colleagues from North Shore University Health System (Evanston, IL), explore the benefit of (RAI) treatment following surgery to remove the thyroid in patients with PTC, and whether survival benefit relates to tumor size. In a retrospective study of nearly 285,000 patients treated over 13 years, with a mean follow-up of 7 years, the authors found that 47% of patients had RAI therapy and it showed a small but statistically significant survival benefit regardless of the tumor size.
Carrie Lubitz, M.D., M.P.H., Massachusetts General Hospital (Boston), and coauthors previously described a novel blood-based assay for detecting the V600E mutation in the BRAF gene in patients with melanoma. The BRAFV600E mutation is the most common genetic alteration in patients with PTC and is associated with a poorer prognosis, higher risk of metastasis and mortality, and resistance to RAI therapy. In the presentation "Detection of Circulating BRAFV600E in Patients with Papillary Thyroid Carcinoma," Lubitz et al. used the assay to measure circulating BRAFV600E levels in blood samples from patients with PTC and compared the results to conventional BRAFV600E assays. Circulating BRAFV600E levels were detectable in the blood of PTC patients, suggesting the feasibility of using the assay for diagnosis, post-operative surveillance, and to monitor treatment response to BRAF inhibitors.
Carmelo Nucera, M.D., Ph.D., Harvard Medical School and Beth Israel Deaconess Medical Center (Boston, MA) and colleagues discovered a large non-coding RNA (LincRNA) neighboring the thyroid peroxidase (TPO) gene that is present in significantly lower numbers in BRAFV600E-positive PTC tissue samples than in normal thyroid tissue. The LincRNA is specifically associated with thyroid tissue compared to other human tissues or cell types. The authors propose that the LincRNA might have an important role in regulating iodine metabolism associated gene expression and could serve as a biomarker for monitoring patients undergoing targeted therapies and for early diagnosis of BRAFV600E-PTC. They describe their findings in the presentation "Identification of Iodine Metabolism-Associated Large Non-coding RNA (LincRNA) Differentially Expressed in BRAFV600E-postivie Papillary Thyroid Cancer Versus Normal Thyroid Tissue."
"The identification of new circulating markers, if validated, should improve both the diagnosis and longitudinal follow-up of patients with papillary thyroid cancer," says Robert C. Smallridge, M.D. President Elect of the ATA.
Source:
American Thyroid Association (ATA)

Thyroid Cancer Genomics May Redefine Diagnosis, Treatment

The genomic landscape of papillary thyroid cancer (PTC), the most common form of thyroid cancer, has just been redefined with respect to its somatic molecular alterations.
In a new study published October 23 in Cell, the analysis identifies new mutations, expands on information of alterations already known, and provides insights into what the future may hold for the diagnosis and clinical management of patient with thyroid nodules and PTCs.
"This understanding of the genomic landscape of thyroid cancer will refine how it's classified and improve molecular diagnosis. This will help us separate those patients who need aggressive treatment from those whose tumor is never likely to grow or spread," Thomas J. Giordano, MD, PhD, professor of pathology at the University of Michigan Medical School, Ann Arbor, said in a university press release.
TCGA Research Network
The Cancer Genome Analysis (TCGA), a project funded by the National Institutes of Health, has led the way in redefining molecular landscapes for several cancers, including breast, lung, ovary, and colon cancers.
In this report, an analysis was undertaken in the largest collection of PTCs from patients primarily without radiation exposure, which is a known PTC risk factor. Tumor samples and matched germline DNA were available from 496 patients and included various histologic types: classical type, follicular variant, tall-cell variant, and some uncommon types of PTC.
The first level of analysis provided mutational information by using different "platforms" (see figure below). At this level, several new mutated genes were identified, including EIF1AXPPM1D, andCHEK2. Mutations were also identified in MAPK-related genes, BRAFNRASHRAS, and KRAS. Mutations in tumor suppressor genes (eg, TP53RB1PTEN), numerous gene fusions (eg, RET andBRAF fusions) and TERT were in the newly expanded mutational landscape of PTC.

Unlike many other cancers, the thyroid genome is considered relatively quiet because it harbors fewer mutations and copy number alterations. This meant that the researchers could perform some integrated bioinformatic analyses not possible with more complex cancers.
Using data from multiple genomic platforms, TCGA researchers could define in greater detail mutational "drivers." In this analysis, researchers identified drivers in all but 3.5% of cases — down from 25% of tumors without apparent driving alterations.
The drivers were divided into two main groups: "BRAFV600E-like" mutations and "RAS-like" mutations. Using a 71-gene signature, a BRAFV600E-RAS score (BRS: –1 to +1) was developed, which showed a distinct separation of BRAFV600E-like from RAS-like tumors (see figure in the article's Graphical Abstract).
A thyroid differentiation score (TDS), developed on the basis of expression of thyroid metabolism and function genes, indicated a correlation across all the tumors analyzed. RAS-like tumors were uniformly highly differentiated, while BRAFV600E tumors displayed significant variation in differentiation. Currently, allBRAF-mutant PTCs are considered to be a homogeneous clinicopathologic group. However, the TDS indicates otherwise.
Ramifications for PTC Classification
"We will no longer be able to talk of BRAFV600E as a single tumor type. Indeed, the granular level at which we have teased out some of these mutations tells us that tumors with the most commonly understood and studied mutation in thyroid cancer — BRAFV600E — are not as homogeneous as is commonly believed," Dr Giordano said.
"PTC is too nonspecific a diagnosis," said Ronald J. Koenig, MD, PhD, also from the University of Michigan Medical School but not associated with the study. "It is not easy to predict how a panel of mutations will make a cancer more aggressive. That's where TCGA researchers have helped," he toldMedscape Medical News.
This comprehensive analysis informed TCGA researchers that thyroid cancer, especially the follicular variant of PTC, begs to be reclassified according to molecular characteristics.
This would allow endocrinologists and oncologists to identify slow-growing, highly differentiated tumors from aggressive, less-differentiated tumors, Dr Giordano told Medscape Medical News.
Indeed, classical-type PTCs are rich in RET rearrangements, follicular-variant PTCs have RAS-like molecular features, and the aggressive tall-cell variants are enriched in BRAFV600E.
Designing clinical trials to evaluate targeted agents can benefit from these observations and the underlying genetics can help inform trial results, Dr Giordano said.
But although TCGA network has re-examined the molecular landscape across several tumor types, the role of the pathologist is not going to be passé, Dr Koenig told Medscape Medical News. The two are going to complement each other, he added.
Implications for Clinical Practice
In the clinical management of PTC, genetic testing is not routine, Dr Koenig told Medscape Medical News: "Genetic testing is done in less than 5% of patients."
In patients with thyroid nodules whose biopsy specimens are indeterminate, a gene signature can help assess the risk for malignancy and therefore can aid in clinical decision making, he said. There is no standard of care for integrating genetics into the clinical management of patients with PTC, Dr Koenig said.
According to Dr Koenig, "Most patients are cured by surgery or radioactive iodine [RAI] treatment." Differentiation is important if RAI therapy is to work, Dr Giordano explained to Medscape Medical News. Undifferentiated carcinomas and some less differentiated PTCs have lost their avidity for RAI. Indeed, RAI-resistant PTCs are enriched in BRAFV600E mutations, he added.
Although Dr Koenig agrees that TCGA has expanded understanding of the molecular defects across PTC, he indicated that most patients with BRAFV600E> actually do well with the current standard of care. TCGA has helped us understand how thyroid cancers with one bad gene can become aggressive when they accumulate additional mutations, he added.
In this regard, a separate but recent study published online October 20 in the Journal of Clinical Oncology found that the prevalence of BRAFV600E in 2000 patients with PTC was 48.5%. More significantly, PTC recurred in 20.9% of these patients. The investigators concluded that patients withBRAFV600E PTC were at an 82% higher risk for PTC recurrence compared with patients who did not have this mutation.
Those researchers indicated that PTC recurred even in patients with low-risk disease and suggested that "management of these patients is highly controversial."
Indeed, TCGA researchers would suggest that molecular testing of these patients may help in the risk stratification and clinical management of these patients.
"Our study will take molecular testing to the next level," Dr Giordano told Medscape Medical News. The expanded mutational landscape of thyroid cancer will improve the preoperative evaluation of thyroid nodules and better inform surgical decisions by helping to distinguish patients with benign nodules from those with thyroid cancer, he added.
This study was funded by several grants from the National Institutes of Health. Multiple authors identified relationships with industry.
Cell. 2014;159:676-690. Abstract

Veracyte Announces Positive Coverage Policy for Afirma® Gene Expression Classifier... -- SOUTH SAN FRANCISCO, Calif., Dec. 2, 2014 /PRNewswire/ --

Veracyte Announces Positive Coverage Policy for Afirma® Gene Expression Classifier... -- SOUTH SAN FRANCISCO, Calif., Dec. 2, 2014 /PRNewswire/ --:



'via Blog this'

Avoiding Progression to Type 2 Diabetes

Avoiding Progression to Type 2 Diabetes:



'via Blog this'

Type 2 Diabetes In Middle Age Ups Risk Of Impaired Cognitive Function Later On

Type 2 Diabetes In Middle Age Ups Risk Of Impaired Cognitive Function Later On:



'via Blog this'

Tuesday, November 25, 2014

Cediranib Clinical Trial Update

Hi, Everyone - It's been pointed out to me that I haven't sent a clinical trial update for awhile.  It's been about 6 months, so maybe it is time to let you know how things are going.

I just completed Cycle 8 of my new clinical trial using the drug Cediranib.  Like my old clinical trial, Cediranib is an oral drug.  I'm on a 4-week cycle.  Unlike my old trial, there is no break between cycles, so a cycle ends on Day 28 and starts right up the next morning.

As with my old study, my study location is Mercy Hospital in St. Louis.  I fly or drive down every 4 weeks to pick up the next cycle's drug supply.  There's the possibility that I'll be allowed to pick up a 2-cycle supply after a year on the study, which would be nice.  I have a C/T scan every 8 weeks to see how things are going.  This drug is not a cure, but it's hoped is that it will prevent the existing tumors from growing and prevent the emergence of new tumors.  I had a scan last week and got a good report:  No new tumors and no growth in the existing tumors.  My old study kept me going for 7 years and I'm hoping this study will beat that!

The side effects for this drug are similar to my old study but so far have not been as severe.  The main ones for me have been high blood pressure, foggy-headedness, digestive unhappiness, hoarseness, and fatigue.  A couple weeks ago I was diagnosed with a new one:  Type 2 Diabetes.  This is very common on the drug.  I've started pricking my finger for a blood glucose test every morning and am taking an oral drug (Glipizide) to help control it.  The best thing about having diabetes is that now I can lose some weight without the oncologists having a fit!  (It's actually kind of fun watching them try to process it.  Cognitive Dissonance is an amusing thing in an MD.  That's why they're not lawyers, I guess.*;) winking)  

So far, I've been able to fly out of Lincoln to get to St. Louis instead of driving to Omaha and flying out of there.  It's unusual for Lincoln fares to be anywhere close to Omaha's, so I hope it lasts.  The only bad thing about flying out of Lincoln is that the time is St. Louis is so short I don't get to see Sara's family and I really miss that.

Everyone in St. Louis is tense waiting for the Ferguson grand jury to issue it's findings.  When I was down there last week there was a lot of increased security on the train platforms and in the bus transport centers.  One of the med techs I work with lives in Ferguson.  She's scared to go to work in the morning for fear she won't be able to get home in the evening.  Her grandkids are scared to go to school.  From the bus, one can see businesses with boarded up windows and big signs announcing that they're still open.  The hospital has a disaster plan in place and there's extra security there, too.  It feels like a war is about to break out.  I can't imagine what it's like to live with that every day.

The other big mystery in St. Louis is trying to figure out why gas is 60 cents cheaper than in Lincoln.  I suspect that's one mystery that's not going to be solved.


Hope you're all well and a Happy Thanksgiving.  Thanks for your continuing prayers and support!

John